Mifeprex in NEJM
Executive Summary
Four deaths from C. sordellii in women using Mifeprex and misoprostol are discussed in the Dec. 1 New England Journal of Medicine. All four cases involved vaginal use of misoprostol; Mifeprex labeling states that misoprostol should be taken orally. Accompanying editorial urges regulators to "keep this rare complication in perspective and not over-react to scant data"...
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.